Docetaxel
- Generic Name
- Docetaxel
- Brand Names
- Taxotere, Docetaxel Accord, Docetaxel Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C43H53NO14
- CAS Number
- 114977-28-5
- Unique Ingredient Identifier
- 699121PHCA
- Background
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...
- Indication
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
- Associated Therapies
- -
Study of Novel Treatment Combinations in Patients With Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 593
- Registration Number
- NCT05633667
- Locations
- 🇧🇷
Hospital Mae de Deus, Porto Alegre, Brazil
🇧🇷Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-03, Porto Alegre, Brazil
🇬🇧Birmingham Heartlands Hospital,Substudy-03, Birmingham, United Kingdom
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2023-10-24
- Target Recruit Count
- 366
- Registration Number
- NCT05631262
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 474
- Registration Number
- NCT05629949
- Locations
- 🇨🇳
Cancer Hospital,Chinese Academy of Medical Sciences, Beijing, China
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 220
- Registration Number
- NCT05625412
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles, California, United States
🇺🇸Local Institution - 0019, Los Angeles, California, United States
🇦🇷Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
- Conditions
- Interventions
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 114
- Registration Number
- NCT05616624
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Inova Schar Cancer Institute, Fairfax, Virginia, United States
A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 50
- Registration Number
- NCT05567835
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Baylor College of Medicine Medical Center - McNair Campus, Houston, Texas, United States
🇺🇸Baylor St. Luke's Medical Center, Houston, Texas, United States
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 105
- Registration Number
- NCT05553808
- Locations
- 🇸🇪
GSK Investigational Site, Uppsala, Sweden
SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05552807
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, China
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT05543629
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
🇺🇸Local Institution - 0096, Costa Mesa, California, United States
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyDrug: CisplatinProcedure: Magnetic Resonance ImagingRadiation: Diffusing Alpha-emitter Radiation TherapyProcedure: Modified Barium Swallow StudyProcedure: Intensity-Modulated Proton TherapyDrug: DocetaxelOther: ObservationRadiation: Intensity-Modulated Radiation TherapyProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 320
- Registration Number
- NCT05541016
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.